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John F. Moorhead3, Yaxi Chen1 & Xiong Z. Ruan1,3
Insulin resistance is closely related to inflammatory stress and the mammalian target of rapamycin/
S6 kinase (mTOR/S6K) pathway. The present study investigated whether rapamycin, a specific 
inhibitor of mTOR, ameliorates inflammatory stress-induced insulin resistance in vitro and in 
vivo. We used tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) stimulation in HepG2 
hepatocytes, C2C12 myoblasts and 3T3-L1 adipocytes and casein injection in C57BL/6J mice to 
induce inflammatory stress. Our results showed that inflammatory stress impairs insulin signaling 
by reducing the expression of total IRS-1, p-IRS-1 (tyr632), and p-AKT (ser473); it also activates 
the mTOR/S6K signaling pathway both in vitro and in vivo. In vitro, rapamycin treatment reversed 
inflammatory cytokine-stimulated IRS-1 serine phosphorylation, increased insulin signaling to 
AKT and enhanced glucose utilization. In vivo, rapamycin treatment also ameliorated the impaired 
insulin signaling induced by inflammatory stress, but it induced pancreatic β-cell apoptosis, reduced 
pancreatic β-cell function and enhanced hepatic gluconeogenesis, thereby resulting in hyperglycemia 
and glucose intolerance in casein-injected mice. Our results indicate a paradoxical effect of rapamycin 
on insulin resistance between the in vitro and in vivo environments under inflammatory stress and 
provide additional insight into the clinical application of rapamycin.
Insulin resistance is the central component of metabolic syndrome and an important pathophysio-
logical factor in the initiation and development of type 2 diabetes (T2DM), atherosclerosis (AS) and 
non-alcoholic fatty liver disease (NAFLD)1,2. Insulin resistance is defined as a clinical state in which 
insulin-responsive tissues (including liver, muscle and adipose tissue) are insensitive to normal or ele-
vated insulin levels and subsequently trigger a series of pathophysiological events. Classic insulin signal-
ing that involves insulin receptor, insulin receptor substrates (IRS), phosphatidylinositol-3-kinase (PI3K) 
and the protein kinase AKT plays a central role in the metabolic actions of insulin in many types of cells 
and tissues3,4. In pathophysiological states, such as inflammatory stress, free fatty acid loading and oxi-
dative stress, uncontrolled inhibitory serine phosphorylation of IRS-restrained tyrosine phosphorylation 
and hijacked insulin signaling5,6. It is now well-accepted that the dysregulation of IRS phosphorylation 
is a major parameter resulting in insulin resistance; however, the precise cellular mechanism is largely 
unknown.
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Low-grade systemic inflammation is a feature of obesity and insulin resistance7. Since Hotamisligil 
and colleagues first showed that pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α ) 
was able to induce insulin resistance in four different rodent models of obesity and diabetes8, further 
inflammatory markers and mediators including C-reactive protein (CRP) and interleukin-6 (IL-6) were 
reported to be closely associated with T2DM9,10. The molecular mechanisms by which inflammation 
causes insulin resistance have been intensively investigated in the last decade. It has been demonstrated 
that adipose-derived pro-inflammatory cytokines (adipokines), such as TNF-α , IL-6, monocyte che-
moattractant protein-1 (MCP-1) and serum amyloid A (SAA), may act locally in autocrine and paracrine 
manners or play a systemic role in modulating insulin actions11–14. Numerous investigations indicate 
that inflammation or individual cytokines inhibit insulin signaling by several mechanisms, such as 
serine-phosphorylation of IRS-1, induction of suppressor of cytokine signaling 3 (SOCS-3), and the 
activation of c-Jun NH2-terminal kinase (JNK) or inhibitor kappa B kinase β /nuclear transcription factor 
kappa B (IKKβ /NF-κ B) pathway in insulin-target tissues12,15–18. However, much is still unknown regard-
ing the molecular mechanism of inflammation leading to serine-phosphorylation of IRS-1.
Recently, our previous study and studies by others demonstrated that inflammation can activate 
the mammalian target of the rapamycin (mTOR) pathway19–21. The mTOR/S6 kinase (S6K) pathway 
is a critical signaling component in the development of obesity-linked insulin resistance22,23. Sustained 
activation of the mTOR/S6K pathway by nutrients or prolonged insulin treatment promotes insulin 
resistance through increased IRS-1 serine phosphorylation, leading to a reduction in IRS-1 function 
and impaired activation of the PI3K/AKT pathway, thereby creating a negative feedback loop of insulin 
action. Whether inflammation leads to phosphorylation of IRS-1 at the serine site through the mTOR 
pathway remains to be discussed.
Rapamycin is a very selective inhibitor of the mTOR/S6K pathway, with no inhibitory activity toward 
other known kinases, even at concentrations in the high nanomolar range24. Accordingly, the inhibition 
of mTOR by rapamycin was found to attenuate serine phosphorylation of IRS-1, restore insulin action on 
the PI3K/AKT pathway and prevent the insulin-resistant effects of excess nutrients on insulin-mediated 
glucose transport in muscle and adipose cells25–28. Paradoxically, it appears that a significant side effect 
of chronic rapamycin treatment is deranged glucose metabolism29. Chronic administration of rapamy-
cin substantially impairs glucose tolerance and insulin action under conditions of excess nutrients30. 
However, the effects of rapamycin on insulin action and glucose metabolism under the condition of 
inflammatory stress remain totally unknown in vivo.
The current study was undertaken to investigate whether inflammatory stress impairs insulin signal-
ing by activating the mTOR/S6K pathway in cultured cells (HepG2 cells, C2C12 myoblasts and 3T3-L1 
adipocytes) and C57BL/6J mice. Moreover, we aimed to investigate the effects of rapamycin on inflam-
matory stress-induced insulin resistance and glucose metabolism disorder both in vitro and in vivo. The 
different effects of rapamycin on insulin resistance between in vivo and in vitro environments under 
inflammatory stress are further discussed in this study.
Results
Rapamycin recovered inflammatory cytokine-induced impairment of glucose uptake and 
consumption in vitro. HepG2 cells, C2C12 myoblasts and 3T3-L1 adipocytes were treated with TNF-
α or IL-6 to induce inflammatory stress. Our data showed that glucose (2-NBDG) uptake and glucose 
consumption were decreased in the TNF-α and IL-6-treated groups compared with controls in the three 
types of cell lines in the absence and presence of insulin (Fig. 1a–f), suggesting that inflammatory stress 
impaired glucose utilization in vitro.
We further analyzed the effect of rapamycin on glucose metabolism in the three types of cell lines. 
Glucose uptake and consumption were improved in the rapamycin plus TNF-α or IL-6 groups compared 
with cells treated with TNF-α or IL-6 alone in the absence and presence of insulin (Fig. 1a–f), suggesting 
that rapamycin ameliorates inflammatory stress-induced insulin resistance in vitro.
Rapamycin improved inflammatory cytokine-induced defects in insulin signaling in vitro. The 
total protein levels of IRS-1 and tyrosine phosphorylated IRS-1 were reduced in the TNF-α and 
IL-6-treated groups compared to controls. In addition, serine AKT phosphorylation was downregulated 
in the inflammatory cytokine loading group compared with controls; however, no significant change was 
observed in total AKT expression (Fig. 2a).
We also observed that serine phosphorylated IRS-1 was increased after TNF-α or IL-6 loading 
(Fig. 2a), implying that inflammatory stress impaired insulin signaling. As the potential effector mole-
cules involved in insulin resistance, the levels of mTOR, phosphorylated mTOR and downstream phos-
phorylated S6K were increased in the TNF-α and IL-6-treated groups (Fig.  2a), suggesting that the 
mTOR/S6K pathway may be involved in insulin resistance under inflammatory stress.
Next, we evaluated the effects of rapamycin on impaired insulin signaling induced by inflammatory 
stress in three types of cell lines. Rapamycin inhibited the inflammatory stress induced p-mTOR and 
p-S6K expression, reduced the levels of serine phosphorylated IRS-1, and increased total IRS-1 and 
tyrosine phosphorylated IRS-1 expression (Fig. 2b). Quantitative densitometry analysis of western blot 
was also performed (see Supplementary Fig. S1 online). These results suggested that rapamycin improves 
the insulin signaling pathway under inflammatory stress.
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Casein injection induced chronic systemic and local inflammation in C57BL/6J mice. Chronic 
low-grade systemic inflammation was induced in C57BL/6J mice using a combination of a high-fat 
diet and a subcutaneous injection of 10% casein on alternate days for 14 weeks. There were significant 
increases in the SAA and TNF-α concentration in the serum of casein-injected mice compared with con-
trols (Fig. 3a). We also measured local inflammatory cytokine production in the liver, skeletal muscle and 
adipose tissue of C57BL/6J mice. The mRNA expression of TNF-α and MCP-1, and the protein expres-
sion of TNF-α , MCP-1, scavenger receptor type A (SR-A) and NF-κ B in the liver, muscle and adipose of 
casein-injected mice were significantly increased compared with those of control mice (Fig. 3b,c). These 
results suggested that inflammatory stress was successfully induced in C57BL/6J mice.
Chronic inflammation induced insulin resistance and lipid disorder in vivo. The fasting glucose 
levels were significantly increased in casein-injected mice compared to controls. After a glucose chal-
lenge, the blood glucose concentration in the inflamed group was persistently higher than the control 
group, especially at the 120-minute time point of the glucose challenge (Fig.  4a left), suggesting that 
chronic inflammation induced glucose intolerance in mice. After insulin loading, blood glucose levels 
decreased less in the casein-treated group (Fig.  4b left), suggesting that chronic inflammation reduced 
insulin sensitivity in vivo. We also analyzed the lipid levels in C57BL/6J mice. As shown in Table  1, 
triglyceride (TG) and free fatty acid (FFA) levels in the liver and muscle were significantly increased in 
casein-treated mice, while serum and adipose tissue lipid content was unchanged/unaffected, suggesting 
that chronic systemic inflammation led to ectopic lipid deposition in non-adipose tissue.
Rapamycin improved IRS-1/AKT signaling pathway but aggravated insulin resistance in vivo. 
Inflammatory stress inhibited the levels of total IRS-1, tyrosine phosphorylated IRS-1, p-AKT and 
increased the levels of serine phosphorylated IRS-1, which is parallel to the overactivation of the mTOR/
S6K pathway in the liver, muscle and adipose tissue of C57BL/6J mice (Fig.  5a). Rapamycin inhibited 
Figure 1. Effects of inflammatory stress and rapamycin on glucose utilization in vitro. HepG2 cells, 
differentiated C2C12 myoblasts and 3T3-L1 adipocytes were incubated in serum-free medium for 24 h. The 
medium was then replaced by fresh serum-free medium containing 0.04 mmol/L palmitic acid alone or with 
TNF-α (25 ng/ml) or IL-6 (20 ng/ml) in the absence or presence of rapamycin (10 ng/ml) for 24 h. Glucose 
uptake (a–c) was determined with a fluorescent D-glucose analog, 2NBDG, after treatment with or without 
insulin. Glucose consumption (d–f) was measured as described in the Materials and Methods section and 
normalized by cell protein. The results are shown as the mean ± SD (n = 6). **P < 0.05 versus control (basal), 
*P < 0.05 versus control (insulin), ##P < 0.05 versus inflammatory cytokine treated group (basal), #P < 0.05 
versus inflammatory cytokine treated group (insulin).
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the inflammation-induced upregulation of p-mTOR, p-S6K and serine p-IRS1, and increased total IRS-1, 
tyrosine p-IRS1 and p-AKT levels in liver, muscle and adipose of C57BL/6J mice (Fig. 5b). Quantitative 
densitometry analysis of western blot was also performed (see Supplementary Fig. S2 online). The results 
suggested that inflammatory stress impaired insulin signaling probably via the activation of the mTOR/
S6K pathway in vivo, which can be blocked by rapamycin.
Unexpectedly, glucose (Fig. 4a right) and insulin (Fig. 4b right) tolerance tests from C57BL/6J mice 
showed that rapamycin aggravated glucose intolerance under inflammatory stress. However, TG and FFA 
levels in the liver and muscle of C57BL/6J mice were markedly decreased in the presence of rapamycin 
(Table  1), suggesting that rapamycin could ameliorate lipid accumulation induced by inflammation in 
non-adipose tissue.
Rapamycin treatment enhanced hepatic gluconeogenesis in inflamed mice. Because rapa-
mycin had an opposite effect on glucose metabolism under inflammatory stress in vitro and in vivo, we 
focused on the contribution of the liver to the glucose intolerance of rapamycin-treated mice. Chronic 
inflammation upregulated the mRNA (Fig. 6a,b) and protein (Fig. 6c,d) expression of two key glucone-
ogenic enzymes, phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G-6-Pase), 
in the liver. Notably, rapamycin treatment resulted in even higher expression of PEPCK and G-6-Pase 
than the casein-treated group (Fig. 6a–d).
Rapamycin induced pancreatic β-cell dysfunction and apoptosis in inflamed mice. In accord-
ance with our previous study, chronic inflammation exacerbated pancreatic β -cell dysfunction and apop-
tosis. In the rapamycin-treated group, the islet size and insulin content were further decreased (Fig. 7a,b), 
suggesting that rapamycin impairs β -cell function in casein-injected mice. In addition, we found that 
Figure 2. Effects of inflammatory stress and rapamycin on protein expression of insulin signaling 
pathway in vitro. HepG2 cells, C2C12 myoblasts and 3T3-L1 adipocytes were treated with insulin prior to 
harvest. (a) IRS1, p-IRS1 (tyr), and p-AKT, proteins of insulin signaling, were downregulated in the TNF-α - 
or IL-6-treated group. The proteins involved in the mTOR/S6K pathway were upregulated in the presence 
of inflammatory cytokines. (b) Under inflammatory stress, rapamycin inhibited the protein expression of 
mTOR, p-mTOR and p-S6K, while increasing the proteins involved in insulin signaling.
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rapamycin increased β -cell apoptosis (Fig.  7c) and upregulated pancreatic Bax/Bcl2 mRNA expression 
(Fig.  7d). To gain further insight into the mechanism underlying rapamycin-mediated impairment in 
pancreatic islets, we determined the expression of key participants in β -cell functional integrity, namely 
pancreatic duodenal homeobox-1 (PDX-1), glucokinase (GK), and glucose transporter 2 (GLUT2). 
Figure 3. Casein injection induced chronic systemic inflammation in vivo. The C57BL/6J mice fed with 
high-fat diet (HFD) were randomly assigned to receive a subcutaneous injection of normal saline (control 
group) or casein (casein group). (a) The levels of SAA and TNF-α in the serum of casein-injected mice 
were significant higher. The mRNA (b) and protein (c) levels of TNF-α and MCP-1 in the liver, muscle and 
adipose tissues increased in the casein group, which was parallel to the upregulation of SR-A and NF-kB 
protein in the liver, muscle and adipose tissue. The histogram represents the mean ± SD (n = 3) of the 
densitometric scans for protein bands, normalized by comparison with β -actin, and expressed as folds of 
control. *P < 0.05 versus control.
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Rapamycin significantly reduced pancreas PDX-1, GLUT2 and GK mRNA levels (Fig. 7e), and the serum 
insulin concentration in the rapamycin treatment group was lower (Fig. 7f). Together these results clarify 
why rapamycin ameliorates impaired insulin signaling induced by inflammation, but does not improve 
the overall glucose tolerance in vivo.
Discussion
Chronic systemic inflammation plays an important role in the pathogenesis of multiple metabolic disor-
ders, including insulin resistance, T2DM, NAFLD, AS, obesity and dyslipidemia. In this study, we used 
two important inflammatory cytokine, TNF-α and IL-6, to induce inflammatory stress in HepG2 cells, 
C2C12 myoblasts and 3T3-L1 adipocytes. We verified the results from in vitro study using an in vivo 
model of chronic inflammation by subcutaneous casein injection in C57BL/6J mice fed a HFD. Casein 
injection is an established method for the induction of chronic systemic inflammation in mouse mod-
els31,32. Compared to other sole cytokine-treated models or local inflammation models, casein injection 
increased multiple cytokine levels in the serum, which is more likely to mimic the chronic systemic 
inflammatory state observed in patients with inflammatory stress33. In this model, serum SAA and 
TNF-α levels were significantly increased, and TNF-α , MCP-1, SR-A and NF-kB in the liver, muscle and 
adipose tissue were upregulated, confirming that we established a successful model of chronic inflam-
mation (Fig. 3). We further evaluated the effects of inflammation on glucose metabolism in vitro and in 
vivo. TNF-α or IL-6 downregulated insulin-stimulated glucose uptake and consumption in three types 
Figure 4. Effects of chronic inflammation and rapamycin on glucose and insulin tolerance in vivo. The 
C57BL/6J mice fed with a high-fat diet (HFD) were randomly assigned to receive a subcutaneous injection 
of normal saline, casein, casein plus vehicle and casein plus rapamycin. (a) Glucose tolerance tests (glucose-
stimulated blood glucose concentrations, IGTT) performed after 14 weeks of treatment. (b) Insulin tolerance 
tests (insulin-stimulated blood glucose concentrations, IITT) performed at the end of the experiments. The 
results represent the mean ± SD (n = 6). * P < 0.05 versus control. #P < 0.05 versus casein plus vehicle group.
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of cell lines, and casein injection decreased glucose and insulin tolerance in C57BL/6J mice, indicating 
that the inflammatory stress promoted insulin resistance (Figs 1 and 4).
mTOR/S6K has received much attention recently because of its central role in modulating cell prolif-
eration and affecting tumorigenesis as well as its involvement in insulin resistance34,35. From a collective 
body of work, mTOR/S6K signaling has emerged as a key player in insulin resistance resulting from a 
variety of conditions, including excessive nutrients and hyperinsulinemia. To investigate the molecu-
lar link between inflammatory stress and insulin resistance, we investigated the role of the mTOR/S6K 
pathway on insulin signaling. Rapamycin (also known as Rapamune® (sirolimus)) is a specific inhibitor 
of the mTOR pathway. Here, we investigated the contribution of rapamycin to insulin resistance and 















Control 4.62 ± 0.58 2.31 ± 0.55 69.55 ± 11.10 0.12 ± 0.04 36.64 ± 3.37 0.49 ± 0.14 2.42 ± 0.22 12.60 ± 4.79
Casein 4.28 ± 0.23 2.59 ± 0.10 112.01 ± 11.89* 0.31 ± 0.05* 50.17 ± 5.70* 0.67 ± 0.12* 2.19 ± 0.24 11.79 ± 0.96
Casein+ Vehicle 4.41 ± 1.02 1.85 ± 0.30 187.89 ± 38.01 0.45 ± 0.17 52.17 ± 6.09 0.51 ± 0.05 2.89 ± 0.81 17.94 ± 4.86
Casein+ Rapa 5.22 ± 1.88 1.58 ± 0.18 91.56 ± 42.25§ 0.14 ± 0.05§ 35.23 ± 11.19§ 0.39 ± 0.01§ 1.82 ± 0.36§ 18.45 ± 2.06
Table 1.  The lipid level in the serum, liver, muscle and adipose of C57BL/6J mice fed with HFD. 
TG and FFA levels in the serum, liver, muscle and adipose tissue of C57BL/6J mice fed with HFD were 
measured as described in Materials and Methods, and results represent the mean  ±  SD (n = 6). *P < 0.05 
versus Control. §P < 0.05 versus Casein + Vehicle.
Figure 5. Effects of chronic inflammatory and rapamycin on protein expression of insulin signaling in 
vivo. (a) IRS1, p-IRS1 (tyr), and p-AKT, proteins of insulin signaling, were downregulated in casein group. 
The proteins involved in the mTOR/S6K pathway were upregulated in the presence of casein. (b) Under 
inflammatory stress, rapamycin inhibited the protein expression of mTOR, p-mTOR and p-S6K, while 
increasing the proteins involved in insulin signaling.
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glucose metabolism under inflammatory stress both in vitro and in vivo. In this study, we showed that 
rapamycin improved the attenuated IRS1/PI3K/AKT insulin signaling pathway induced by inflamma-
tory stress, increased the levels of total IRS-1 and tyrosine phosphorylated IRS-1 and decreased ser-
ine phosphorylation of IRS-1 both in vitro and in vivo (Figs  2b and 5b). Our results suggested that 
inflammatory stress induced serine phosphorylation of IRS-1, impairing insulin signaling probably via 
activation of the mTOR/S6K pathway in vitro and in vivo. There may be some limitations to the phar-
macological approach of using rapamycin to block mTOR signaling. Rapamycin inhibits the activity of 
the two mTOR complexes. Inhibition of mTORC1 occurs immediately following binding of rapamycin 
to FK506-binding protein-12 (FKBP12), whereas prolonged exposure to rapamycin is required to block 
formation of nascent mTORC2. Therefore, genetic attenuation of mTORC1 signaling or deletion of the 
mTORC1 substrate S6K may help to strengthen our conclusion. Further, assessing the dose-dependent 
effect of inflammatory factors on mTOR signaling activities as well as conducting a correlation analysis 
may provide more evidence to support this conclusion.
In recent years, rapamycin has been used as a key component of the immunosuppressive regimen in 
clinical organ transplantation. It was suggested that rapamycin may hold promise as a drug for diabetes 
treatment. However, it was found that organ transplant patients treated with rapamycin have a higher 
prevalence of glucose intolerance than others. This may suggest that rapamycin disrupts glucose metab-
olism under certain conditions, such as abnormal immune response or inflammation induced by organ 
transplantation. Here, the beneficial effect of rapamycin on glucose uptake and consumption in vitro 
was contradictory to the aggravated glucose intolerance and reduced insulin sensitivity observed in vivo 
under inflammatory stress (Fig. 4).
Given the severe glucose intolerance and hyperglycemia in rapamycin-treated mice under inflam-
mation, we first evaluated the contribution of the liver to this phenomenon. Liver gluconeogenesis is 
driven by the availability of gluconeogenic substrates and the activity of two key gluconeogenic enzymes, 
PEPCK and G-6-Pase. In the re-fed state, insulin suppresses gluconeogenesis by transcriptional down-
regulation of PEPCK and G-6-Pase36. Our data revealed that casein treatment results in higher levels 
of PEPCK and G-6-pase in the mouse liver. Rapamycin further enhanced hepatic gluconeogenesis by 
Figure 6. Rapamycin treatment enhanced hepatic gluconeogenesis. (a) PEPCK and (b) G-6-Pase mRNA 
expression in the liver of C57BL/6J mice. The graphs depict mRNA expression in the liver of target genes 
corrected for the expression of β -actin as the housekeeping gene. (c) Representative western blotting of 
PEPCK and G-6-pase proteins in the liver. (d)The histogram represents the mean ± SD (n = 3) of the 
densitometric scans for protein bands from three experiments, normalized by comparison with β -actin, and 
expressed as folds of control. *P < 0.05 versus control, #P < 0.05 versus casein plus vehicle.
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Figure 7. Rapamycin induced pancreatic β-cell dysfunction and apoptosis in vivo. (a) Hematoxylin–eosin 
staining in the pancreas. (b) Insulin immunohistochemistry. Magnification, 10× (top panels); 40× (bottom 
panels). (c) Apoptosis in situ. Apoptosis of insulin-expressing cells on islet sections was determined by the 
TUNEL assay. Representative examples of pancreatic islets stained by immunofluorescence for insulin (red), 
marker of cell apoptosis TUNEL (green), and nuclear stain DAPI (blue) imaged at 100× in casein plus vehicle 
(upper) and casein plus rapamycin (lower). (d) Effects of rapamycin on the mRNA expression of Bax/Bcl2 in the 
pancreas of C57BL/6J mice. (e) Effects of rapamycin on β -cell gene expression. The expression of GK, GLUT2 
and PDX-1 in islets was determined by real-time quantitative RT-PCR using β -actin as an internal standard. (f) 
Serum insulin concentrations in C57BL/6J mice were analyzed using a mouse-specific insulin ELISA kit. The 
results represent the mean ± SD (n = 6). *P < 0.05 versus control, #P < 0.05 versus casein plus vehicle.
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upregulating PEPCK and G-6-pase expression in casein-injected mice (Fig. 6), which is consistent with 
previous reports that chronic rapamycin treatment increased hepatic gluconeogenesis in rats29.
We subsequently investigated the effects of rapamycin on pancreatic insulin secretion. PDX-1 acts in 
β -cells as a house-keeping transcription factor for insulin gene expression37,38. GK and GLUT2 are two 
key components of the glucose-sensing machinery responsible for glucose-inducible insulin release38–40. 
We showed that rapamycin significantly reduced pancreas PDX-1, GLUT2 and GK mRNA levels accom-
panied by β -cell apoptosis (Fig. 7). Serum insulin concentrations in the rapamycin treatment group were 
lower, suggesting that rapamycin impairs pancreatic β -cell function and reduces insulin synthesis and 
secretion. It has been shown that mTOR plays a critical role in the regulation of β -cell mass. Conversely, 
the inhibition of mTOR by rapamycin causes loss of β -cell function and viability38,41. This increases our 
understanding of why rapamycin was beneficial to impaired insulin signaling in vitro but further exac-
erbated glucose intolerance under conditions of inflammatory stress in vivo.
Abnormal lipid metabolism is one of the features of metabolic syndrome. Elevated FFA has been 
shown to impair insulin action and to be a risk factor for the development of T2DM. We have previously 
demonstrated that rapamycin plays important roles in controlling cholesterol homeostasis19,20. In this 
study, we showed that rapamycin treatment ameliorates chronic inflammation-induced disordered lipid 
metabolism in non-adipose tissue. Rapamycin treatment lowered TG and FFA deposition, especially in 
the liver and muscle of casein-injected mice (Table 1).
Taken together, this study suggests that inflammatory stress induces the dysregulated phosphorylation 
of IRS-1 and impairs insulin signaling probably by activating the mTOR/S6K pathway in vitro and in 
vivo. Rapamycin has the potential to improve insulin signaling and reduce lipid accumulation in the liver 
induced by chronic low-grade systemic inflammation, but it also has a negative effect on β -cell function 
and hepatic gluconeogenesis, which may cause hyperglycemia. Therefore, the overall negative effect of 
rapamycin on glucose homeostasis is due to a combination of these factors. A method to harness the 
beneficial effects of rapamycin while maintaining β -cell function and inhibiting hepatic glucose output 
could potentially lead to a stream of novel medications for the treatment of diabetes.
Methods
Cell culture and induction of differentiation. HepG2 cells were cultured in growth medium con-
taining Dulbecco’s modified Eagle’s medium (DMEM)/high-glucose medium, 10% fetal calf serum, 
2 mmol/l glutamine, 100 U/ml penicillin, and 100 μ g/ml streptomycin. Mouse C2C12 myoblasts were 
maintained in DMEM/ high-glucose medium with 10% fetal calf serum, 2 mmol/l glutamine, 100 U/ml 
penicillin, and 100 μ g/ml streptomycin at a 70–80% confluency. To initiate differentiation, cells were 
allowed to reach 100% confluency, and the medium was changed to DMEM containing 2% horse 
serum and changed every 2 days. Full differentiation, with myotube fusion and spontaneous twitching 
was observed at 5 days. 3T3-L1 preadipocytes were cultured in growth medium containing DMEM/ 
high-glucose medium with 10% calf serum, 2 mmol/l glutamine, 100 U/ml penicillin, and 100 μ g/ml 
streptomycin. Two-day post-confluent (day 0) cells were introduced to differentiation medium with 
DMEM/ high-glucose containing 10% fetal bovine serum (FBS), 10 μ g/ml insulin (Sigma-Aldrich, St. 
Louis, MO, USA), 1 μ M dexamethasone (Sigma) and 0.5 mM 3-isobutyl-1-methylxanthine (Sigma) until 
day 2. Cells were fed with DMEM/ high-glucose supplemented with 10% FBS and 10 μ g/ml insulin for 2 
days followed every other day with DMEM/ high-glucose containing 10% FBS. All experiments were car-
ried out in serum-free DMEM medium containing 0.2% fatty acid-free bovine serum albumin (Sigma), 
and the cells were subjected to 0.04 mmol/l palmitic acid (PA, Sigma) or inflammatory stress by loading 
25 ng/mL TNF-α or 20 ng/ml IL-6 (Peprotech Asia, Rehovot, Israel) in the absence or presence of 10 ng/
ml rapamycin (914.19 mol wt, code AY-22989-39, Wyeth Pharmaceutics) for 24 h at 37 °C with 5% CO2.
Animal model. Animal care and experimental procedures were performed with approval from the 
Animal Care Committee of Chongqing Medical University in accordance with the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals (NIH publication number 8023, revised 1978). 
Eight-week-old male C57BL/6J mice were fed a Western diet (Harlan, TD88137) containing 21% fat and 
0.15% cholesterol for 14 weeks. The mice were randomly assigned to receive subcutaneous injections of 0.5 
milliliter (ml) normal saline or 0.5 ml 10% casein every other day. To investigate the effect of rapamycin, 
C57BL/6J mice with a combination of a high-fat diet and subcutaneous injection of 10% casein were ran-
domly assigned to receive either a subcutaneous injection of 0.2 ml vehicle or 0.2 ml rapamycin (2 mg/kg 
body weight). The injections were performed every other day, and the mice were culled 14 weeks after 
the first injection. At termination, blood samples were taken for lipid profile and cytokine assay and the 
tissues were collected for further detection.
Measurement of insulin signaling. For in vitro experiments examining insulin signaling, HepG2 
cells were harvested after 100 nM insulin stimulation for 15 min, and differentiated C2C12 and 3T3-L1 
cells were harvested after 100 nM insulin stimulated for 30 min. For in vivo biochemical analysis of insu-
lin signaling, another set of mice in each group was fasted overnight and injected intraperitoneally with 
insulin at a dose of 5 mU/g body weight (Sigma, St. Louis, MO, US) for 10 min before adipose tissues, 
liver and skeletal muscle were taken and snap-frozen in liquid nitrogen immediately after resection and 
stored at − 80 °C.
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Serum analysis. Serum tumor necrosis factor-alpha (TNF-α ), serum amyloid A protein (SAA) and 
free fatty acid (FFA) concentrations were measured by enzyme-linked immunosorbent assay (ELISA) 
kits (HuaMei Biotech, Wu Han, China). Glucose and insulin levels in the serum were detected using the 
enzyme coupling colorimetric method and ELISA kit, respectively.
Glucose uptake. Glucose uptake was performed as described previously42, with some modification 
using 2-NBDG (2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy- d-glucose; Invitrogen, USA). 
In brief, after serum starvation for 24 h, the cells were treated with an inflammatory mediator with or 
without rapamycin at 37 °C for 24 h. Cells were washed three times with wash buffer (20 mM HEPES, 
pH 7.4, 140 mM NaCl, 5 mM KCl, 2.5 mM MgSO4, and 1 mM CaCl2) then incubated in buffer transport 
solution (wash buffer containing 10 mM 2-NBDG with or without 100 nmol/L insulin). The 2-NBDG 
uptake kinetics of cells were measured prior to the irradiation experiment by incubating with buffer 
transport solution at 37 °C for 20 min. Cell protein content was determined following cell lysis in 1 M 
NaOH. 2-NBDG uptake was expressed as picomoles per minute per milligram of protein.
Glucose consumption. After serum starvation for 24 h, cells were treated with inflammatory medi-
ator or rapamycin (containing 100 nmol/L insulin or not) at 37 °C for 24 h. For analysis of glucose con-
centrations before and after the 24-hour treatment, the medium was spun down in a centrifuge column 
and subjected to glucose analysis in a GOPOD kit (Rongsheng Biotech, Shanghai, China) according to 
the manufacturer’s instructions.
Western blotting. Cytoplasmic and nuclear proteins were extracted from liver, skeletal muscle and 
white adipose tissue using a commercial kit. Sample proteins were separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) in a Bio-Rad Mini Protean apparatus and were then 
transferred to a PVDF membrane. The membranes were blocked with 5% (w/v) non-fat dried milk 
and incubated with primary antibodies [anti-SR-A, anti-TNF-α , anti-MCP-1, anti-NF-kB, anti-IRS1, 
anti-p-IRS1 (tyr632), anti-p-IRS1 (ser270), anti-AKT, anti-p-AKT (ser473), anti-mTOR, anti-p-mTOR 
(S2448), anti-p-S6K(thr421/ser424), anti-β -actin, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, 
USA)], followed by incubation with a secondary horseradish peroxidase conjugated antibody. Finally, 
detection procedures were performed using ECL Advance Western Blotting Detection kit (Amersham 
Bioscience, Piscataway, NJ, US). Band intensity volumes were measured with ImageJ software.
Quantitative measurement of intracellular TG and FFA. Quantitative measurements of TG and 
FFA were performed using commercial kits (Jiancheng, Nanjing, China and HuaMei Biotech, Wu Han, 
China). Briefly, samples were collected and lipids were extracted by addition of 1 ml solvents (TG: hep-
tane/isopropanol = 2/3.5, FFA: chloroform/heptane/methanol = 5/5/1). The lipid phase was collected and 
vacuum dried. The concentrations of TG and FFA were analyzed using standards and normalized using 
total protein from tissues.
Glucose tolerance tests. Before the glucose tolerance tests, mice were starved overnight but allowed 
free access to water. Glucose tolerance was tested by the intraperitoneal injection of 2 mg D-glucose/g 
body weight (Sigma). Blood glucose concentrations were determined in blood taken from the cut tail 
tip before glucose administration and 15, 30, 60, and 120 minutes after the administration. The glu-
cose concentrations were determined using an ACCU-CHEK Advantage blood glucose meter (Roche, 
Mannheim, Germany).
Insulin Tolerance Tests. Prior to the insulin tolerance tests, mice were starved for 4 hours but allowed 
free access to water. Insulin tolerance was measured by intraperitoneal injection of 1 mU insulin/g 
body weight (Sigma, St. Louis, US). The glucose concentrations in blood were determined using an 
ACCU-CHEK Advantage blood glucose meter (Roche, Mannheim, Germany), which were taken from 
the cut tail tip, before and 15, 30, 60, and 120 minutes after the administration of insulin.
Histology. Pancreas from C57BL/6J mice were sequentially fixed, dehydrated, infiltrated and cut into 
5-μ m paraffin-embedded tissue sections. Sections were stained with hematoxylin-eosin (HE).
Immunohistochemistry. Sections were cut from embedded pancreatic slices and deparaffinized in 
dimethyl benzene. The immunohistochemistry procedures were set up according to the manufactur-
er’s instructions (Zsbio, Beijing, China). Sections were blocked using 3% hydrogen peroxide and 10% 
serum and then incubated with primary antibody (anti-insulin, Bioss, Beijing, China). Avidin anti-rabbit 
antibody served as the secondary antibody followed by horseradish peroxidase anti-avidin antibody. 
Horseradish peroxidase activity was detected using a DAB solution (Zsbio, Beijing, China). Finally, the 
reaction was stopped, and sections were counterstained with hematoxylin.
β-cell apoptosis. Free 3-hydroxy strand breaks resulting from DNA degradation were detected 
using the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) technique 
according to the manufacturer’s instructions (DeadEnd™ Fluorometric TUNEL System, Promega, USA). 
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Apoptosis in pancreatic islet was assessed by scoring the number of cells with pyknotic nuclei after 
DAPI staining. To detect the β -cells, 5-μ m slices of paraffin-embedded tissue were incubated with rab-
bit anti-insulin antibody, followed by detection using the fluorescently labeled secondary antibody. The 
samples were immediately evaluated by fluorescence microscopy (ZEISS, Germany) for positively stained 
apoptotic nuclei.
Real-time Reverse Transcription Polymerase Chain Reaction. Total RNA were isolated from 
liver, skeletal muscle, white adipose tissue and pancreas homogenates from C57BL/6J mice using Trizol 
reagent (Takara Life Technologies, Carlsbad, Japan). Real-time reverse transcription polymerase chain 
reaction (PCR) was performed in a Bio-Rad Sequence Detection System (Hercules, US) using SYBR 
Green dye (Applied Biosystems Inc, Foster City, US) according to the manufacturer’s protocol.
All the primers were designed by Primer Express Software V2.0 (Applied Biosystems). The fol-
lowing oligonucleotide primers were used for TNF-α (F:5′ -CAGCCGATGGGTTGTACCTT-3′ , R:5′ - 
GGCAGCCTTGTCCCTTGA-3′ ). MCP-1 (F:5′ -GTCTGTGCTGACCCCAAGAAG-3′ , R:5′ -TGGTTCC 
GATCCAGGTTTTTA-3′ ). Bax (F:5′ -GGCCTTTTTGCTACAGGGTTT-3′ , R:5′ -GTGTCTCCCCAGC 
CATCCT-3′ ). Bcl2 (F:5′ -CCTGTGGATGACTGAGTACCTGAA-3′ , R:5′ - CTACCCAGCCTCCGTTAT 
CCT-3′ ). PDX-1 (F:5′ -CGCGTCCAGCTCCCTTT-3′ , R:5′ -CCACGCGTGAGCTTTGGT-3′ ). GLUT2 
(F:5′ -TGGAAGGATCAAAGCAATGTTG-3′ , R:5′ -CATCAAGAGGGCTCCAGTCAA-3′ ). GK (F:5′ -GC 
TTTTGAGACCCGTTTTGTG-3′ , R:5′ -GCCTTCGGTCCCCAGAGT-3′ ). PEPCK (F:5′ -ATCTCCTTT 
GGAAGCGGATATG-3′ , R:5′ -CGCAACGCAAAGCATTTCTT-3′ ). G6pase (F:5′ -TCGGCCTATCTCGG 
GTCTT-3′ , R:5′ -GCCGCCCAACACTTGGT-3′ ). β -actin (F:5′ -CGATGCCCTGAGGCTCTTT-3′ , R:5
′ -TGGATGCCACAGGATTCCAT-3′ ). To normalize expression data, β -actin was used as an internal 
control gene.
Statistical analysis. Results are presented as means ± SD (n = 6). In all experiments, data were eval-
uated for statistical significance using one-way ANOVA analysis of variance followed by Q-test. A differ-
ence was considered significant if the P value was less than 0.05.
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